Research programme: inflammation therapies - Cytos Biotechnology
Alternative Names: CYT 020 TNFQbLatest Information Update: 25 Apr 2014
At a glance
- Originator Cytos Biotechnology
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Inflammation
Most Recent Events
- 24 Apr 2014 Discontinued - Preclinical for Inflammation in Europe (unspecified route)
- 17 Aug 2011 Suspended - Preclinical for Inflammation in Europe (unspecified route)